These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 25375908

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Development of aldose reductase inhibitors for the treatment of inflammatory disorders.
    Chatzopoulou M, Pegklidou K, Papastavrou N, Demopoulos VJ.
    Expert Opin Drug Discov; 2013 Nov; 8(11):1365-80. PubMed ID: 24090200
    [Abstract] [Full Text] [Related]

  • 4. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
    Kovacikova L, Prnova MS, Majekova M, Bohac A, Karasu C, Stefek M.
    Molecules; 2021 May 12; 26(10):. PubMed ID: 34066081
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N.
    Expert Opin Investig Drugs; 2008 Apr 12; 17(4):575-81. PubMed ID: 18363521
    [Abstract] [Full Text] [Related]

  • 8. The role of aldose reductase inhibitors in diabetic complications: recent trends.
    Kaul CL, Ramarao P.
    Methods Find Exp Clin Pharmacol; 2001 Oct 12; 23(8):465-75. PubMed ID: 11838322
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.
    Prior AM, Thapa M, Hua DH.
    Mini Rev Med Chem; 2012 Apr 12; 12(4):326-36. PubMed ID: 22303947
    [Abstract] [Full Text] [Related]

  • 11. [Research progress in aldose reductase].
    Gu J, Yan J, Wu W, Huang Q, Ouyang D.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr 12; 35(4):395-400. PubMed ID: 20448367
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
    Sonowal H, Ramana KV.
    Curr Med Chem; 2021 Apr 12; 28(19):3683-3712. PubMed ID: 33109031
    [Abstract] [Full Text] [Related]

  • 17. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications.
    Pathania S, Randhawa V, Bagler G.
    PLoS One; 2013 Apr 12; 8(4):e61327. PubMed ID: 23613832
    [Abstract] [Full Text] [Related]

  • 18. Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
    Lee CM, Jung HA, Oh SH, Park CH, Tanaka T, Yokozawa T, Choi JS.
    Arch Pharm Res; 2015 Jun 12; 38(6):1090-8. PubMed ID: 25315636
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.